Exploiting the DNA-damage repair defect of BRCA1-deficient pancreatic cancer cells in drug therapy
In this study we show that BRCA1-deficient murine pancreatic carcinoma cells are sensitive to DNA damaging drugs like Mitomycin C and Cisplatin.
Preview
Rights
Use and reproduction:
No license. The provisions of the German Copyright Act (UrhG) apply.
Please note that individual components of the publication may be subject to other licensing or copyright conditions.
Cite
Citation style:
Could not load citation form.